Solid Biosciences Inc. continues to push forward with its gene therapy efforts for rare neuromuscular diseases, highlighted by dosing the first patient in the Phase 3 IMPACT DUCHENNE trial. Despite clinical momentum, the company faces steep financial challenges, marked by mounting net losses and heavy cash burn reflective of intensive R&D spending. The firm's strong cash position supports ongoing operations but signals dependency on future capital raises to sustain pipeline advancement and eventual commercialization. Regulatory complexities, orphan drug advantages, and potential partnership needs underscore the multifaceted landscape shaping Solid’s near-term outlook.